Weekly Recap: Ropidoxuridine trial halt and Q2 2026 loss narrows to $3.15M

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) is winding down Ropidoxuridine trials to reallocate staff and budget into AI, marketing and digital infrastructure tied to United Dogecoin after a public offering and PIPE, even as Q2 2026 showed $0 revenue and a $3.15M net loss.Previous Week Rec…